Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin–angiotensin–aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Samuel Seidu, Setor Kunutsor, Pinar Topsever, Kamlesh Khunti.
+31 648546892
secretary@pcdeurope.org
